Is there anything “difficult or mysterious” about identifying a principle of general application? How does it save a patent from an insufficiency attack? When may a claim incorporating such a principle cover inventive improvements without being insufficient? And, does the Supreme Court’s decision in Regeneron v Kymab answer any of these questions?
Justin Lambert has closely followed the progress of this case through the UK Courts, attended the UKSC hearing and been involved in related overseas litigation concerning the same technology. Justin will lead this webinar in which he will address the above questions and explain the significance of the terms “hybrid antibody”, “immunological sickness” and “reverse chimeric locus” that are key to understanding the Supreme Court decision.